Business Context and Reporting Period
The filing is AlloVir, Inc.’s Form 10-K for the fiscal year ended December 31, 2020; it does not identify Kalaris Therapeutics, Inc. AlloVir is a late clinical-stage biotechnology company developing allogeneic, off-the-shelf virus-specific T-cell therapies. Its lead candidate, Viralym-M, targets five viruses in immunocompromised transplant patients. The company had five product candidates targeting 12 viruses and no products approved for commercial sale.
AlloVir completed its initial public offering on August 3, 2020, issuing 18.7 million shares at $17.00 per share and receiving $292.0 million in net proceeds. Its common stock began trading on Nasdaq under “ALVR” on July 30, 2020.
Financial Performance and Liquidity
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Revenue | $0 | $0.2 million | Down $0.2 million |
| Research and development expense | $49.7 million | $16.2 million | Up $33.4 million |
| General and administrative expense | $21.6 million | $10.6 million | Up $11.0 million |
| Total operating expenses | $71.3 million | $26.9 million | Up $44.4 million |
| Net loss | $69.8 million | $23.8 million | Loss increased $45.9 million |
| Net loss per share | $2.59 | $18.54 | Not directly comparable due to IPO and share-count changes |
| Cash used in operating activities | $60.8 million | $20.2 million | Use increased $40.6 million |
| Cash, cash equivalents and short-term investments | $356.3 million | $126.1 million | Up $230.2 million |
Operating expenses increased primarily because of expanded Viralym-M, ALVR106 and ALVR109 development, clinical-trial activity, outsourced manufacturing, headcount, consultants and public-company costs. The company reported no product revenue and expects significant operating losses to continue. Profit margins are not meaningful because the company has no commercial product sales.
At December 31, 2020, cash and cash equivalents were $122.7 million and short-term U.S. Treasury investments were $233.7 million. Total liabilities were $17.8 million, consisting mainly of lease liabilities, accrued expenses and payables. The filing does not disclose material traditional debt or credit facilities. Management estimated that existing liquidity would fund operations and capital expenditures into 2023, subject to assumptions that may prove incorrect.
Cash provided by financing activities was $292.0 million, principally from the IPO. Cash used in investing activities was $169.5 million, primarily from purchases of short-term investments. Stockholders’ equity was $353.1 million at year-end, compared with a deficit of $51.5 million at December 31, 2019, following the IPO and conversion of preferred stock into common stock.
Material Changes Versus the Prior Comparable Period
- Revenue fell to zero after AlloVir terminated its CPRIT grant; 2019 revenue was $0.2 million.
- Research and development expense more than tripled, driven by Viralym-M clinical and manufacturing costs, ALVR106 development, ALVR109 COVID-19 trial costs and higher personnel costs.
- General and administrative expense approximately doubled as the company expanded and incurred public-company, legal, accounting, insurance and personnel costs.
- Net loss increased from $23.8 million to $69.8 million, while accumulated deficit reached $125.1 million.
- Liquidity increased materially following the IPO, and all outstanding convertible preferred stock converted into 39.9 million common shares.
- AlloVir entered into additional BCM licensing and research arrangements in November 2020, including a three-year research collaboration requiring approximately $6.0 million of payments.
Guidance, Outlook, Risks and Unusual Items
Management planned to have up to three Phase 3 pivotal trials and three Phase 2 proof-of-concept trials for Viralym-M by the end of 2021. The initial Phase 3 trial addressed virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem-cell transplantation. Additional programs included ALVR106 for respiratory viruses, ALVR109 for COVID-19, ALVR107 for chronic hepatitis B and ALVR108 for HHV-8-associated diseases.
- ALVR106’s FDA IND was cleared in the fourth quarter of 2020, with a Phase 1/2 trial planned for the 2021-2022 respiratory-virus season.
- BCM initiated the ALVR109 proof-of-concept trial in the fourth quarter of 2020; topline data were expected in the second half of 2021.
- Preclinical IND-enabling studies for ALVR107 and ALVR108 were planned for the second half of 2021.
- Viralym-M had received FDA RMAT designation, EMA PRIME designation and EMA orphan medicinal product designation. These designations do not assure approval or necessarily shorten development timelines.
- In the CHARMS Phase 2 open-label trial, 93% of 58 evaluable HSCT patients achieved a complete or partial response by six weeks. The filing cautions that the trial was not powered for statistical significance and that open-label, early-stage results may not predict later controlled-trial outcomes.
- Six grade 5 serious adverse events, or deaths, occurred in CHARMS; none were considered treatment-related. The company reported no treatment-related safety signal beyond risks expected in the HSCT population, but additional trials remain necessary.
- COVID-19 disrupted clinical activities and could delay enrollment, manufacturing, supply, regulatory inspections and access to capital.
- Manufacturing depends on third-party CMOs, academic facilities, ElevateBio/BaseCamp and limited or single-source suppliers. Process qualification, scale-up, comparability and contamination risks could delay development.
- The company relies substantially on intellectual property licensed from Baylor College of Medicine. License termination for uncured default or failure to meet obligations could impair development and commercialization.
- Contractual obligations at year-end totaled approximately $25.7 million, including $8.0 million of purchase obligations, $6.0 million of BCM collaboration commitments and $11.7 million of operating lease obligations. Potential milestone and royalty payments were excluded because they were not fixed or determinable.
- The company had no material legal proceedings and no off-balance-sheet arrangements reported at year-end.
Most Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for AlloVir, Inc., not Kalaris Therapeutics, Inc.
- Verify the company’s current cash runway against the “into 2023” estimate and the pace of quarterly cash burn.
- Track results, enrollment and regulatory status of Viralym-M’s pivotal and proof-of-concept trials, particularly the hemorrhagic-cystitis study.
- Assess whether the preliminary CHARMS response and safety data are replicated in randomized, placebo-controlled trials.
- Monitor ALVR106 and ALVR109 trial initiation, enrollment and data, including the impact of changing COVID-19 treatment standards.
- Review manufacturing validation, supplier redundancy, capacity commitments and the transition to ElevateBio/BaseCamp.
- Review BCM license terms, development milestones, royalties and termination provisions.
- Evaluate future financing needs, potential dilution, stock-based compensation and insider or related-party arrangements with ElevateBio.